US FDA approves high-concentration, citrate-free formulation of Cyltezo® (adalimumab-adbm) injection, Boehringer ...
RIDGEFIELD, Conn., May 1, 2024 /PRNewswire/ --Boehringer Mannheim Group announced today that the U.S. Food and Drug Administration (FDA) has approved the high-concentration, citrate-free formulation of Cyltezo® (adalimumab-adbm), the company' …